Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005538 | 1.00 | RAB9A (0.70) | RAB9AKMT2AEPHX2NPC1ATM | |
| SCHEMBL4005534 | 1.00 | RAB9A (0.70) | RAB9AKMT2AEPHX2NPC1ATM | |
| SCHEMBL613408 | 0.95 | RAB9A (0.77) | RAB9AKMT2AEPHX2NPC1ATM | |
| SCHEMBL4961383 | 0.95 | RAB9A (0.77) | RAB9AKMT2AEPHX2NPC1ATM | |
| SCHEMBL5243879 | 0.94 | RAB9A (0.79) | RAB9AKMT2AEPHX2NPC1ATM | |
| SCHEMBL4307015 | 0.91 | RAB9A (0.74) | RAB9AKMT2AEPHX2NPC1ATM | |
| SCHEMBL4307011 | 0.91 | RAB9A (0.74) | RAB9AKMT2AEPHX2NPC1ATM | |
| SCHEMBL4006602 | 0.87 | KMT2A (0.68) | RAB9AKMT2AEPHX2TSHRMEN1 | |
| SCHEMBL4006595 | 0.87 | KMT2A (0.68) | RAB9AKMT2AEPHX2TSHRMEN1 | |
| SCHEMBL611046 | 0.87 | RAB9A (0.68) | RAB9AKMT2AEPHX2NPC1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | claimed |
| EP-1778229-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1778229-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
| WO-2006020598-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | RAB9A 1641/4885KMT2A 3418/4885EPHX2 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.